Radiochemotherapy in Anal Cancer: cCR, clinical outcomes and quality of life using two different treatment schedules

Santo, Sara Di; Trignani, Marianna; Neri, Matteo; Milano, Angelo; Innocenti, Paolo; Taraborrelli, Maria; Augurio, Antonietta; Vinciguerra, A.; Tommaso, M. Di; Ursini, Lucia Anna; Pilla, Angelo Di; Nicola, Marta Di; Genovesi, Domenico

doi:10.1016/j.rpor.2014.11.001

Cited by 3 publications

(2 citation statements)

References 32 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported rate of FI following radiotherapy ranged, from 0 to 44% [18,[31][32][33][34][35][36][37][38][39][40][41][42]. Between 0.5 and 10.9% of anal cancer survivors were reported to have needed a colostomy due to severe anal sphincter dysfunction at a median follow-up of 32.4 months to 8.6 years [43][44][45][46][47][48][49][50][51].…”

Section: Fecal Incontinencementioning

confidence: 99%

Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review

et al. 2018

View full text Add to dashboard Cite

Introduction: There is a paucity of data on incidence and mechanisms of long-term gastrointestinal consequences after chemoradiotherapy for anal cancer. Most of the adverse effects reported were based on traditional external beam radiotherapy whilst only short-term follow-ups have been available for intensity-modulated radiotherapy, and there is lack of knowledge about consequences of doseescalation radiotherapy. Method: A systematic literature review. Results: Two thousand nine hundred and eighty-five titles (excluding duplicates) were identified through the search; 130 articles were included in this review. The overall incidence of late gastrointestinal toxicity was reported to be 7-64.5%, with Grade 3 and above (classified as severe) up to 33.3%. The most commonly reported late toxicities were fecal incontinence (up to 44%), diarrhea (up to 26.7%), and ulceration (up to 22.6%). Diarrhea, fecal incontinence and buttock pain were associated with lower scores in radiotherapy specific quality of life scales (QLQ-CR29, QLQ-C30, and QLQ-CR38) compared to healthy controls. Intensity-modulated radiation therapy appears to reduce late toxicity. Conclusion: Late gastrointestinal toxicities are common with severe toxicity seen in one-third of the patients. These symptoms significantly impact on patients' quality of life. Prospective studies with control groups are needed to elucidate long-term toxicity.

show abstract

Section: Fecal Incontinencementioning

confidence: 99%

Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Many studies received their data from follow-up examinations without using questionnaires 3,9,10 or focused only on general side effects without going into detail. 11–13 In 1999, Allal et al 14 described changes in long-term QoL especially for sexual function. Poor sexual function scores seem to persist even several years after chemoradiation.…”

Section: Discussionmentioning

confidence: 99%

Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects

Koerber

Seither

Slynko

et al. 2018

Tumori

View full text Add to dashboard Cite

Introduction: We evaluated acute and chronic side effects of 3D conformal radiotherapy (3D-CRT) and intensity-modulated radiation therapy (IMRT) in female patients with anal carcinoma and accessed correlations between dosimetric parameters and the considered toxicities. Methods: For 70 women with anal cancer treated at our department, acute and chronic side effects and quality of life (QoL) were evaluated with questionnaires using the Common Terminology Criteria for Adverse Events (CTCAE v. 4.0.) and Late Effects in Normal Tissue, Subjective, Objective Management and Analytic Scales (LentSoma) before, during, and after the treatment. Results: Forty-seven out of 70 (67%) patients completed the questionnaire and were enrolled in the study. Only poor urinary stream, loss of pubic hair during chemoradiation, and chronic vaginal dryness were observed more frequently in the 3D-CRT group compared to the IMRT group (univariable logistic regression p = .032, p = .04, p = .049, respectively). After the treatment, 43% in the 3D-CRT group and 29% in the IMRT group reported a severe loss of QoL. A higher proportion among the patients receiving a genital V20 ⩾35% showed grade 1–3 side effects such as chronic dyspareunia ( p = .035; Fisher exact test). Conclusion: Our results suggest that the use of IMRT decreases acute and chronic adverse effects although reduced QoL also occurred in the IMRT group. These effects are likely to be underreported in retrospective studies using physician-reported outcome measures.

show abstract

Management of late adverse effects after chemoradiation for anal cancer

et al. 2021

View full text Add to dashboard Cite

Radiochemotherapy in Anal Cancer: cCR, clinical outcomes and quality of life using two different treatment schedules

Cited by 3 publications

References 32 publications

Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review

Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review

Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects

Management of late adverse effects after chemoradiation for anal cancer

Contact Info

Product

Resources

About